Global Nasal Drug Delivery Technology Market is projected to grow at a CAGR of 9.0% By 2032: Visiongain Research Inc – Yahoo Finance
Visiongain has published a new report entitled the Nasal Drug Delivery Technology Market Report 2022-2032. It includes profiles of Nasal Drug Delivery Technology and Forecasts Market Segment by Containers (Non-Pressurized Containers, Pressurized Containers) Market Segment by System, (Nasal Unidose Devices, Nasal Bi Dose Devices, Nasal Multi Dose Devices) Market Segment by Dosage Form, (Nasal Spray, Nasal Drops and Liquids, Nasal Gels, Nasal Powders, Other Dosage Form) Market Segment by End-User, (Hospitals, Home Health Care, Ambulatory Surgery Centre, Specialty Clinics, Vaccination Centres, Other End-User) Market Segment by Respiratory Diseases, (Allergic Rhinitis, Nasal Congestion, Asthma, Other Respiratory Diseases) Market Segment by Non-Respiratory Diseases, (Alzheimer’s, Cardiovascular, Neuropsychiatry Treatments, Other Non-Respiratory Diseases) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country.
The global nasal drug delivery technology market was valued at US$48,087 million in 2021 and is projected to grow at a CAGR of 9.0% during the forecast period 2022-2032.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/nasal-drug-delivery-market-2022/#download_sampe_div
What are the current market drivers?
The Need for Generic Inhalation and Nasal Spray Drugs Is Increasing Owing to Rise in Geriatric population
Over the next several years, more inhalers and nasal sprays are anticipated to enter the generic market. Individuals are expected to gravitate toward more generic products as more patients are diagnosed with restrictive respiratory disorders such as asthma and chronic obstructive lung disease, and overall health care remains expensive. The generic market forecast for prescription treatments for respiratory disorders is consistently encouraging, and the cheap cost of generic drugs provides significant potential for expansion in this lucrative business. In the coming years, there will be a surge in demand for these generic prescription drugs. The generic business as a whole has undergone tremendous expansion primarily due to patent expirations, which has opened new avenues for the generic’s versions. The inhalation and nasal medication spray markets, in particular, are expected to expand significantly.
Growing Adoption of Nasal Spray Is Being Driven by The Development of Advanced Inhalation and Nasal Spray
The intranasal medication delivery method has provided potential possibilities for the administration of therapeutic drugs in recent decades. They are portable since they are battery-powered and do not require an external power source. Furthermore, dry powder inhalers spread medications in the form of dry particles. Nasal therapy is currently being used to treat chronic respiratory disorders such as COPD and asthma. Inhaled medicinal substances are commonly used to treat COPD, asthma, and other respiratory illnesses. Throughout COPD patients, dry powder nasal inhalers are used to maximize drug dispersion in the system while preventing toxicity.
How has COVID-19 had a significant negative impact on the Nasal Drug Delivery Technology Market?
COVID-19 pandemic reported a positive impact on Nasal Drug Delivery market since many patients preferred undertaking their chronic respiratory disease drug therapy from home thereby propelling the uptake of inhalers from home rather than hospital set ups or OPDs. Also, there was increased uptake of nasal inhalers for treatment of asthma, migraine and other psychological diseases. The pandemic compelled the patients to adopt user friendly modes of drug administration such as nasal drug delivery. Many intranasal drugs were introduced as prophylaxis against COVID-19 including nasal sprays made of povidone-iodine, nitric oxide, ethyl lauroyl arginate hydrochloride and many others. In addition, several pharmaceutical companies ventured into development of vaccines through nasal drug delivery technology and few of them are presently in clinical development phase of which two are live attenuated including one from Codagenix and Serum Institute of India and MV-014-212 from Meissa Vaccines. Moreover, there are two non-replicating viral vectors vaccines including BBV154 from Bharat Biotech International and PIV5-vectored vaccine from CyanVac. There is also one NDV vectored inactivated vaccine from Laboratorio AVi-Mex.
How this Report Will Benefit you?
Visiongain’s 658+ page report provides 368 tables and 366 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global nasal drug delivery technology market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Nasal Drug Delivery Technology. Get the financial analysis of the overall market and different segments including System, container, end-user and capture higher market share. We believe that high opportunity remains in this fast-growing nasal drug delivery technology market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
Where are the market opportunities?
Emerging Opportunities for Nasal Devices
Nasal inhalation devices are subject to ongoing innovation by pharmaceutical firms and device partners to improve the care and support offered to patients, in addition to their intuitive design. In the case of emergency treatments, for example, training kits that closely mimic the real-life experience of administering a nasal spray have been designed with the goal of improving compliance and lowering mortality risk. Lock-out mechanisms on devices are also being developed to improve patient safety, while the introduction of laterally actuated nasal sprays gives more comfort and simplicity for some patient populations. Dose counters have long been recognised as aiding adherence, and fast technological advancements have expanded on this foundation to build an ecosystem of linked devices that encourage higher adherence in a more "active" way. Connected devices offer a powerful potential to create an ecosystem in which a pharmaceutical firm, a patient, and a healthcare practitioner are more intimately interwoven by monitoring, recording, and exchanging data on usage through the internet.
Nasal Drug Delivery Has Evolved into A Highly Versatile Method of Administration for Locally Acting and Systemic Drugs
Nasal drug delivery has grown into a very adaptable form of administration for locally acting and systemic medications, emergency dosages, and long-term illnesses, as well as prophylactic immunizations and breaking new ground in hard therapeutic areas. The fact that patient outcomes have been improved by providing medications and therapies in a fashion that is more accessible and acceptable to the patient, easing their access to the care they require, is at the heart of all of these different applications. Nasal administration is poised to play an ever-larger thanks to continuing innovation by pharmaceutical firms and their drug delivery partners.
Competitive Landscape
The major players operating in the nasal drug delivery technology market are Becton, Dickinson and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., AptarGroup, Inc., AstraZeneca PLC, Presspart Manufacturing, 3M Multinational Conglomerate, Consort Medical plc, Neurelis Inc., PendoPharm Inc., Naveh Pharma Ltd. , These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Nasal drug delivery technology market and leading companies. You will find data, trends and predictions.
Find more Visiongain research reports on Pharma Medical Devices; click on the following links:
Balloon Catheter Market
Drug Delivery Technologies Market
Therapeutic Respiratory Devices Market
Medical Device Contract Manufacturing Market
Artificial Intelligence (AI) in Drug Discovery Market
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter
–
SOURCE Visiongain Limited.
Is Pfizer stock a buy or a sell after the FDA rejected human growth hormone deficiency treatment? Is PFE stock a buy now?
The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.
Merck promised to pay out $750 million if the Peninsula biotech's drugs passed certain clinical and commercial milestones.
Novavax (NASDAQ: NVAX) is arriving more than a year after market leaders Pfizer and Moderna to the coronavirus vaccine finish line. Novavax soared 2,700% in 2020. As of today, Novavax's vaccine has won authorization from more than 30 countries.
The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). The FDA has requested an additional preclinical study before continuing the Phase 1b study of VK0214 in X-ALD, not due to any findings from ongoing or previously completed studies. The Company expects to provide the information to the FDA in Q2 of FY22. Related: Viking Therapeutics' VK0214 Shows Encouraging Safety, Tolerability Profile In
HOUSTON (Reuters) -The chiefs of major U.S. oil companies Occidental Petroleum Corp and ConocoPhillips offered differing outlooks on the growth of U.S. oil output at a conference on Monday, as the industry rebounds from shutdowns during the first stage of the coronavirus pandemic. Oil prices have surged to seven-year highs in the last several weeks, with international benchmark Brent crude hitting nearly $90 per barrel, bolstered by tight worldwide supply and resurgent global demand. ConocoPhillips Chief Executive Officer Ryan Lance told an audience at the Argus Americas Crude Summit in Houston that he was bullish about markets as high oil prices "will persist for a while."
Pfizer stock skidded Monday after the Food and Drug Administration rejected its rare-disease drug — leading a smaller decline for similarly jilted Merck.
AbbVie's blockbuster anti-inflammatory Humira could see eight biosimilars launch next year. Bernstein analyst Ronny Gal is still bullish on AbbVie stock.
(Bloomberg) — Lake Maracaibo is, in many ways, the unlikeliest of homes for a burgeoning shrimp farm industry. After a century of relentless oil drilling, much of it carried out in a reckless and haphazard manner in the final years, its surface is stained by petroleum slicks and choked with rusted-out rigs that stretch high into the sky.Most Read from BloombergStocks Get Crushed in Risk-Off Day as Bonds Rally: Markets WrapUAE Says New Attack Repelled as Yemen’s Houthis Vow MoreCrypto Crash Eras
The study found that CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants, researchers from Brazil and Oxford University said on Monday. China-based Sinovac's vaccine uses an inactivated version of a coronavirus strain that was isolated from a patient in China.
The chronic cough drug was approved in Japan, where it will be marketed under the brand name Lyfnua.
Julie Hyman highlights top business stories, including Wynn Resort's plans to sell its online sports betting business, Peloton suffering a PR setback after a character in 'Billions' suffered a heart attack while riding the Peloton bike, and Ford's debut for its 2022 Bronco Raptor.
(Bloomberg) — Lithium prices are continuing their breakneck ascent in China, with surging electric-vehicle sales underpinning a fivefold gain over the past year.Most Read from BloombergStocks Get Crushed in Risk-Off Day as Bonds Rally: Markets WrapUAE Says New Attack Repelled as Yemen’s Houthis Vow MoreCrypto Crash Erases More Than $1 Trillion in Market ValueChina’s ‘Little Giants’ Are Its Latest Weapon in the U.S. Tech WarSolana Suffers Network Instability in Brutal Week for CryptoChinese lith
Omicron's incubation period is shorter than previous COVID-19 variants. Here's why that matters.
The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE) and OPKO Health Inc's (NASDAQ: OPK) somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for pediatric growth hormone deficiency (GHD). Pfizer is evaluating the FDA's comments. Earlier this week, Japan's Ministry of Health, Labour, and Welfare approved Ngenla (somatrogon) Injection 24 mg Pens and 60mg Pens for the long-term treatment of GHD pediatric patients. In 2021, H
Oil is enjoying its best year since prices topped out at more than $100 per barrel a decade ago. Oil and gas behemoth ExxonMobil (NYSE: XOM) has rallied with it, hitting pre-COVID share prices. ExxonMobil's an integrated oil stock, which means it participates in multiple aspects of the oil and gas industry, including the exploration and extraction of fossil fuels (upstream) and the refining and distribution of fossil fuel products (downstream).
‘No beds for your stroke, no beds for your heart attack, no beds for your car crash, no beds for your sick child’
Illustration by Elizabeth Brockway/The Daily BeastTwo months after scientists in South Africa alerted the world to the new, highly transmissible Omicron variant of the novel coronavirus, the global surge in infections resulting from the variant is finally subsiding.To be clear, exhausted health-care workers in overcrowded hospitals are still fighting to save lives. But many epidemiologists are beginning to look ahead to a post-Omicron world.The pandemic experts The Daily Beast spoke to were unan
The federal government is distributing 400 million masks for the public.
The Omicron variant can survive longer than earlier versions of the coronavirus on plastic surfaces and human skin, Japanese researchers found in laboratory tests. Its high "environmental stability" – its ability to remain infectious – might have helped Omicron replace Delta as the dominant variant and spread rapidly, they said. On plastic surfaces, average survival times of the original strain and the Alpha, Beta, Gamma and Delta variants were 56 hours, 191.3 hours, 156.6 hours, 59.3 hours, and 114.0 hours, respectively.
